In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Clinical Infectious Diseases

Volumn 71, Issue 15, 2020, Pages 732-739

  Yao, Xueting ^a   Ye, Fei ^b   Zhang, Miao ^a   Cui, Cheng ^a   Huang, Baoying ^b   Niu, Peihua ^b   Liu, Xu ^a   Zhao, Li ^b   Dong, Erdan ^a   Song, Chunli ^a   Zhan, Siyan ^a   Lu, Roujian ^b   Li, Haiyan ^a   Tan, Wenjie ^b   Liu, Dongyang ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Chloroquine; Hydroxychloroquine; SARS CoV 2

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE SULFATE; ANTIVIRUS AGENT; HYDROXYCHLOROQUINE;

ABSORPTION RATE CONSTANT; ADULT; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; EC50; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; IN VITRO STUDY; INTRINSIC CLEARANCE; LOADING DRUG DOSE; LUNG PARENCHYMA; MAINTENANCE DRUG DOSE; MALE; MAXIMUM CONCENTRATION; NONHUMAN; OPTIMAL DRUG DOSE; PHARMACOKINETIC PARAMETERS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; REAL TIME REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA VIRUS; TROUGH CONCENTRATION; VERO CELL LINE; VIRTUAL REALITY; ANIMAL; BETACORONAVIRUS; CELL LINE; CHLOROCEBUS AETHIOPS; CORONAVIRUS INFECTION; DRUG EFFECT; LUNG; PANDEMIC; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS PNEUMONIA;

ANIMALS; ANTIVIRAL AGENTS; BETACORONAVIRUS; CELL LINE; CHLOROCEBUS AETHIOPS; CHLOROQUINE; CORONAVIRUS INFECTIONS; HYDROXYCHLOROQUINE; LUNG; PANDEMICS; PNEUMONIA, VIRAL; SEVERE ACUTE RESPIRATORY SYNDROME; VERO CELLS;

EID: 85083058614     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciaa237     Document Type: Article

References (32)

1. Romanelli F, Smith KM, Hoven AD. Chloroquine and hydroxychloroquine as inhibitors of human immunodeficiency virus (HIV-1) activity. Curr Pharm Des 2004; 10:2643-8.
2. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 2004; 323:264-8.
3. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 2:69.
4. Ooi EE, Chew JS, Loh JP, Chua RC. In vitro inhibition of human influenza A virus replication by chloroquine. Virol J 2006; 3:39.
5. Li C, Zhu X, Ji X, et al. Chloroquine, a FDA-approved drug, prevents zika virus infection and its associated congenital microcephaly in mice. EBioMedicine 2017; 24:189-94.
6. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30:269-71.
7. Huang J. Efficacy of chloroquine and lopinavir/ ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study. Available at: http://www.chictr.org.cn/showproj.aspx?proj=49263. Accessed 13 February 2020.
8. Li Y. Ministry of Science and Technology of China: chloroquine phosphate is effective in the treatment of novel coronavirus pneumonia. Available at: http://news.ynet.com/2020/02/17/2388070t70.html. Accessed 17 February 2020.
9. Biot C, Daher W, Chavain N, et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem 2006; 49:2845-9.
10. Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993; 23:82-91.
11. Food and Drug Administration. Physiologically based pharmacokinetic analysesformat and content guidance for industry. August 2018. Available at: https://www.fda.gov/media/101469/download. Accessed 17 February 2020.
12. Hsueh CH, Hsu V, Pan Y, Zhao P. Predictive performance of physiologically-based pharmacokinetic models in predicting drug-drug interactions involving enzyme modulation. Clin Pharmacokinet 2018; 57:1337-46.
13. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497-506.
14. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382:727-33.
15. Collins KP, Jackson KM, Gustafson DL. Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J Pharmacol Exp Ther 2018; 365:447-59.
16. Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 1989; 27:771-9.
17. Adelusi SA, Salako LA. Kinetics of the distribution and elimination of chloroquine in the rat. Gen Pharmacol 1982; 13:433-7.
18. McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med 1983; 75:11-8.
19. Fan HW, Ma ZX, Chen J, Yang XY, Cheng JL, Li YB. Pharmacokinetics and bioequivalence study of hydroxychloroquine sulfate tablets in Chinese healthy volunteers by LC-MS/MS. Rheumatol Ther 2015; 2:183-95.
20. Tett SE, Cutler DJ, Day RO, Brown KF. A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol 1988; 26:303-13.
21. Walker O, Dawodu AH, Salako LA, Alván G, Johnson AO. Single dose disposition of chloroquine in kwashiorkor and normal children-evidence for decreased absorption in kwashiorkor. Br J Clin Pharmacol 1987; 23:467-72.
22. Gustafsson LL, Walker O, Alván G, et al. Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol 1983; 15:471-9.
23. Neuvonen PJ, Kivistö KT, Laine K, Pyykkö K. Prevention of chloroquine absorption by activated charcoal. Hum Exp Toxicol 1992; 11:117-20.
24. Furst DE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 1996; 5(Suppl 1):S11-5.
25. Quintart J, Leroy-Houyet MA, Trouet A, Baudhuin P. Endocytosis and chloroquine accumulation during the cell cycle of hepatoma cells in culture. J Cell Biol 1979; 82:644-53.
26. Ying C, De Clercq E, Neyts J. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. J Viral Hepat 2000; 7:79-83.
27. Abdel-Aziz AK, Shouman S, El-Demerdash E, Elgendy M, Abdel-Naim AB. Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries. Chem Biol Interact 2014; 217:28-40.
28. Chen L, Liu HG, Liu W, et al. [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia.] Zhonghua Jie He He Hu Xi Za Zhi 2020; 43:E005.
29. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020; 16:155-66.
30. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis 2003; 3:722-7.
31. Lianhan S, Jianping Z, Yi H, Du Ronghui, Bin C. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020; 395:683-4.
32. Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther 2015; 17:362.